TALVEY talquetamab

Drug Class

Bispecific GPRC5D-directed CD3 T-cell engager

Mechanism

Binds GPRC5D on myeloma cells and CD3 on T-cells, directing T-cell-mediated cytotoxicity against GPRC5D-positive myeloma cells.

Approved Indication

Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

What This Means For Patients

TALVEY is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2023) — Sources
• EMA — Approved (2023) — Sources

Pivotal Clinical Evidence

• MonumenTAL-1 — Chari et al., N Engl J Med 2022 (NCT03399799) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761337s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/talvey